{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Duchenne+Muscular+Dystrophy&q=exon+skipping",
    "query": {
      "q": "exon skipping",
      "condition": "Duchenne Muscular Dystrophy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Duchenne+Muscular+Dystrophy&q=exon+skipping&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T07:34:08.033Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03508947",
      "title": "Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "WVE-210201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wave Life Sciences USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "5 Years to 18 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2018-01-24",
      "completion_date": "2019-03-06",
      "has_results": false,
      "last_update_posted_date": "2019-04-08",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03508947"
    },
    {
      "nct_id": "NCT03907072",
      "title": "Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "WVE-210201 (suvodirsen)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wave Life Sciences USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "12 Years",
        "sex": "MALE",
        "summary": "5 Years to 12 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2019-09-04",
      "completion_date": "2020-01-09",
      "has_results": true,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Kansas City, Kansas + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907072"
    },
    {
      "nct_id": "NCT02530905",
      "title": "Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "SRP-4045",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "21 Years",
        "sex": "MALE",
        "summary": "7 Years to 21 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2015-10-08",
      "completion_date": "2018-10-03",
      "has_results": true,
      "last_update_posted_date": "2021-05-17",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02530905"
    },
    {
      "nct_id": "NCT07609394",
      "title": "Duchenne Electronic Health Record Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)",
        "Becker Muscular Dystrophy",
        "Dystrophinopathy",
        "Dystrophinopathy Symptomatic Female Carrier"
      ],
      "interventions": [
        {
          "name": "Observational study with patients who may be treated with various disease-modifying therapies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The Duchenne Registry",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2500,
      "start_date": "2022-12-01",
      "completion_date": "2072-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07609394"
    },
    {
      "nct_id": "NCT03992430",
      "title": "A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "Eteplirsen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "13 Years",
        "sex": "MALE",
        "summary": "4 Years to 13 Years · Male only"
      },
      "enrollment_count": 160,
      "start_date": "2020-07-13",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03992430"
    },
    {
      "nct_id": "NCT02740972",
      "title": "Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "NS-065/NCNP-01",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NS Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "9 Years",
        "sex": "MALE",
        "summary": "4 Years to 9 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2016-12",
      "completion_date": "2018-04",
      "has_results": true,
      "last_update_posted_date": "2021-12-07",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 6,
      "location_summary": "Sacramento, California • Gainesville, Florida • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02740972"
    },
    {
      "nct_id": "NCT03675126",
      "title": "An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "SRP-5051",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "4 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2018-12-19",
      "completion_date": "2021-08-25",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 7,
      "location_summary": "Hartford, Connecticut • Gulf Breeze, Florida • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03675126"
    },
    {
      "nct_id": "NCT04956289",
      "title": "Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Viltolarsen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NS Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "8 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2021-07-01",
      "completion_date": "2023-07-13",
      "has_results": true,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04956289"
    },
    {
      "nct_id": "NCT04179409",
      "title": "A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Amondys 45",
          "type": "DRUG"
        },
        {
          "name": "Exondys 51",
          "type": "DRUG"
        },
        {
          "name": "Vyondys 53",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kevin Flanigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "6 Months and older · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2020-02-18",
      "completion_date": "2023-09-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04179409"
    },
    {
      "nct_id": "NCT07608432",
      "title": "Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)",
        "Muscular Dystrophy, Duchenne",
        "Muscular Dystrophy (DMD)",
        "DMD",
        "Muscular Dystrophies",
        "Muscular Dystrophy in Children",
        "Muscular Dystrophy, Duchenne Type",
        "Muscular Dystrophy, Duchenne and Becker Types",
        "Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)",
        "Genetic Disease, Inborn",
        "Genetic Disease, X-Linked",
        "Congenital, Hereditary, and Neonatal Diseases and Abnormalities",
        "Neuromuscular Diseases (NMD)"
      ],
      "interventions": [
        {
          "name": "Zeleciment Rostudirsen (DYNE-251)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dyne Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "4 Years to 18 Years · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2026-06",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-07-24T07:34:08.033Z",
      "location_count": 1,
      "location_summary": "Hillsborough, North Carolina",
      "locations": [
        {
          "city": "Hillsborough",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07608432"
    }
  ]
}